Press Releases

RNAi Therapeutics Market: Recent Developments and Key Players

The RNA interference (RNAi) therapeutics market, which was once a specialized area, is now experiencing rapid growth. In 2023, the market reached USD 1.11 billion and is projected to expand significantly, with an impressive compound annual growth rate (CAGR) of 14.9%. By 2033, the market is expected to surge to USD 4.28 billion.

Small interfering RNA (siRNA) therapy is leading the way, accounting for 64% of the market share in 2023. Cancer treatment remains a key focus, with oncology applications set to dominate the market throughout the forecast period. North America was the leading region, holding a substantial 41% share of the market in 2023.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5115

Emerging Trends and Recent Changes in RNAi Therapeutics

RNA interference (RNAi) therapeutics started to gain momentum in clinical trials after 2008, a decade after the RNAi mechanism was first discovered. Since then, the number of clinical trials using RNAi-based drugs has grown significantly. From 2008 to 2022, the number of published clinical trials in this field increased nearly tenfold, and the number of ongoing trials surged about seven times between 2015 and 2021.

However, there was a noticeable decline in 2022, with a nearly 40% drop in ongoing trials involving small interfering RNA (siRNA) drugs. Despite this setback, siRNAs remain the dominant RNAi molecule used in clinical trials. In 2022, siRNAs made up about 90% of both published and ongoing trials, and this trend has continued into 2023, with nearly all current studies focusing on siRNA-based therapies.

In contrast, short hairpin RNAs (shRNAs) have been used less frequently but have maintained a steady presence in clinical trials over the years. Research involving shRNA-based treatments remains small but consistent. Similarly, studies exploring microRNAs (miRNAs) and miR-shRNAs are limited, with only a few publications and ongoing investigations in this area.

Recent Developments

In January 2023, the US FDA granted Breakthrough Therapy designation to Moderna’s new mRNA vaccine, mRNA-1345. This vaccine is designed to protect adults aged 60 and older from respiratory diseases caused by RSV infection.

In September 2022, Alnylam Pharmaceuticals, Inc. received approval from the European Commission to market their RNAi therapy, AMVUTTRA. This treatment is intended for adults with hereditary transthyretin-mediated (hATTR) polyneuropathy in stage 1 or stage 2.

Key Companies in the RNAi Therapeutics Market

  • Alnylam Pharmaceuticals, Inc.
  • Novartis
  • Arbutus Biopharma
  • Arrowhead Pharmaceuticals
  • Novo Nordisk (Dicerna Pharmaceuticals)
  • Sirnaomics

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/rnai-therapeutics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5115

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Elena Morales

Elena Morales is a healthcare industry expert working at Healthcare Web Wire Consulting Firm, a subsidiary of Towards Healthcare. With her excellent knowledge of the field, Elena helps clients optimize their operations and navigate healthcare regulations. She's dedicated to staying updated on industry trends to make a positive impact on patient care. Elena is known for her professionalism and commitment to excellence, making her a valuable asset to any team.

Recent Posts

Retinitis Pigmentosa Market Key Trends, Developments and Future Outlook

Retinitis Pigmentosa Market Overview Growth and Emerging Opportunities The global retinitis pigmentosa (RP) market was valued at USD 14.02 billion… Read More

4 hours ago

Advanced Drug Delivery Market Recent Developments and Key Players

Advanced Drug Delivery Market Insights The advanced drug delivery market experienced significant growth in 2023, reaching a value of USD… Read More

4 hours ago

Telehealth and Telemedicine Market Report Transforming Healthcare Delivery and Driving Global Growth

Telehealth and Telemedicine Market Key Highlights The telehealth and telemedicine market reached USD 214.55 billion in 2023 and is projected… Read More

4 hours ago

Corticosteroids Market Trends and Growth Outlook

Corticosteroids Market Overview The corticosteroids market was valued at USD 4.71 billion in 2023 and is projected to reach USD… Read More

4 hours ago

Home Healthcare Market Key Players and Industry Insights

Home Healthcare Market Growth and Trends The home healthcare market experienced significant growth in 2023, reaching a value of $192.4… Read More

1 day ago

mHealth Market Transforming Healthcare through Mobile Technology

Growth and Trends in the mHealth Market Key Insights The mHealth market achieved a significant size of USD 60.65 billion… Read More

1 day ago